Rosiglitazone (BRL 49653) potassium, a potent and selective PPARgamma agonist (EC 50: 60 nM, Kd: 40 nM) administered orally, also acts as an activator of TRPC5 (EC 50: 30 µM) and an inhibitor of TRPM3. Widely used in research, it has shown promise in investigating obesity, diabetes, senescence, and ovarian cancer [1] [2] [4] [7].
